Adopting real-time surveillance dashboards as a component of an enterprisewide medication safety strategy

Joint Commission Journal on Quality and Patient Safety

Volumn 37, Issue 7, 2011, Pages 326-332

  Waitman, Lemuel R ^a   Phillips, Ira E ^b   McCoy, Allison B ^c   Danciu, Ioana ^a   Robert, M ^d   Halpenny, M S ^d   Nelsen, Cori L ^a   Johnson, Daniel C ^a   Starmer, John M ^a   Peterson, Josh F ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTICOAGULANT AGENT;

ARTICLE; DECISION SUPPORT SYSTEM; ELECTRONIC MEDICAL RECORD; HOSPITAL PHARMACY; HUMAN; INTERPERSONAL COMMUNICATION; MEDICATION ERROR; ORGANIZATION AND MANAGEMENT; SAFETY;

AMINOGLYCOSIDES; ANTICOAGULANTS; COMMUNICATION; DECISION SUPPORT SYSTEMS, CLINICAL; HUMANS; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MEDICATION ERRORS; PHARMACY SERVICE, HOSPITAL; SAFETY MANAGEMENT;

EID: 79959549889     PISSN: 15537250     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1553-7250(11)37041-9     Document Type: Article

References (25)

1. Leape L.L., et al.: The nature of adverse events in hospitalized patients: Results of the Harvard Medical Practice Study II. N Engl J Med 324:377-384, Feb. 7, 1991.
2. Classen D.C., et al.: Computerized surveillance of adverse drug events in hospital patients. JAMA 266:2847-2851, Nov. 27, 1991.
3. Erratum in: JAMA 267:1922, Apr. 8, 1992.
4. Bates D.W., et al.: Incidence of adverse drug events and potential adverse drug events: Implications for prevention. JAMA 274:29-34, Jul. 5, 1995.
5. Bates D.W., et al.: The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Group. JAMA 277:307-311, Jan. 22-29, 1997. (Pubitemid 27045011)
6. Institute of Medicine: To Err Is Human: Building a Safer Health Care System. Washington, DC: National Academy Press, 2000.
7. The Joint Commission: 2011 National Patient Safety Goals Now Available. http://www.jointcommission.org/standards-information/npsgs.aspx (last accessed Jun. 1, 2011).
8. Fortescue E.B., et al.: Prioritizing strategies for preventing medication errors and adverse drug events in pediatric inpatients. Pediatrics 111(4 pt. 1):722-729, Apr. 2003. (Pubitemid 36402893)
9. Gandhi T.K., et al.: Adverse drug events in ambulatory care. N Engl J Med 348:1556-1564, Apr. 17, 2003. (Pubitemid 36437933)
10. Wysowski D.K., Swartz L.: Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: The importance of reporting suspected reactions. Arch Intern Med 165:1363-1369, Jun. 2005. (Pubitemid 40973418)
11. Brewer T., Colditz G.A.: Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs. JAMA 281:824-829, Mar. 3, 1999. (Pubitemid 29113743)
12. Evans R.S., et al.: Prevention of adverse drug events through computerized surveillance. Proc Annu Symp Comput Appl Med Care 1992:437-441.
13. Rozich J.D., Haraden C.R., Resar R.K.: Adverse drug event trigger tool: A practical methodology for measuring medication-related harm. Qual Saf Health Care 12:194-200, Jun. 2003. (Pubitemid 36723946)
14. Kilbridge P.M., et al.: Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc 13:372-377, Jul.-Aug. 2006. (Pubitemid 43947628)
15. Kilbridge P.M., Alexander L., Ahmad A.: Implementation of a system for computerized adverse drug event surveillance and intervention at an academic medical center. J Clin Outcomes Manage 13:94-100, Feb. 2006.
16. van der Sijs H., et al.: Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 13:138-147, Mar.-Apr. 2006. (Pubitemid 43332904)
17. Lo H.G., et al.: Impact of non-interruptive medication laboratory monitoring alerts in ambulatory care. J Am Med Inform Assoc 16:66-71, Jan. 1, 2009.
18. Phillips I.E., et al.: Improving aminoglycoside dosing through computerized clinical decision support and pharmacy therapeutic monitoring systems. AMIA Annu Symp Proc Nov. 6, 2008:1093.
19. McCoy J.A., et al.: User response to warfarin initiation and modification dosing support tools. AMIA Annu Symp Proc. 2009.
20. McCoy A.B., et al.: A computerized provider order entry intervention for medication safety during acute kidney injury: A quality improvement report. Am J Kidney Dis 56:832-841, Nov. 2010.
21. Cox Z., et al.: Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. Am J Health Syst Pharm 68:624-632, Apr. 1, 2011.
22. Bates D.W., et al.: Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 280:1311-1316, Oct. 21, 1998. (Pubitemid 28473716)
23. Leape L.L., et al.: Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 282:267-270, Jul. 21, 1999. (Pubitemid 29343170)
24. Jha A.K., et al.: Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J Am Med Inform Assoc 15:647-653, Sep.-Oct. 2008.
25. Handler S.M., et al.: Assessing the performance characteristics of signals used by a clinical event monitor to detect adverse drug reactions in the nursing home. AMIA Annu Symp Proc 6:278-282, 2008.